These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
405 related articles for article (PubMed ID: 29342879)
1. Ophthalmic Drug Delivery Systems for Antibiotherapy-A Review. Dubald M; Bourgeois S; Andrieu V; Fessi H Pharmaceutics; 2018 Jan; 10(1):. PubMed ID: 29342879 [TBL] [Abstract][Full Text] [Related]
2. Mechanistic modeling of ophthalmic drug delivery to the anterior chamber by eye drops and contact lenses. Gause S; Hsu KH; Shafor C; Dixon P; Powell KC; Chauhan A Adv Colloid Interface Sci; 2016 Jul; 233():139-154. PubMed ID: 26318359 [TBL] [Abstract][Full Text] [Related]
3. Ocular preparations: the formulation approach. Kaur IP; Kanwar M Drug Dev Ind Pharm; 2002 May; 28(5):473-93. PubMed ID: 12098838 [TBL] [Abstract][Full Text] [Related]
4. Colloidal nanosystems with mucoadhesive properties designed for ocular topical delivery. Silva B; São Braz B; Delgado E; Gonçalves L Int J Pharm; 2021 Sep; 606():120873. PubMed ID: 34246741 [TBL] [Abstract][Full Text] [Related]
9. Sparfloxacin-loaded PLGA nanoparticles for sustained ocular drug delivery. Gupta H; Aqil M; Khar RK; Ali A; Bhatnagar A; Mittal G Nanomedicine; 2010 Apr; 6(2):324-33. PubMed ID: 19857606 [TBL] [Abstract][Full Text] [Related]
10. Colloidal drug delivery system: amplify the ocular delivery. Ali J; Fazil M; Qumbar M; Khan N; Ali A Drug Deliv; 2016; 23(3):710-26. PubMed ID: 24892625 [TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo evaluation of in situ gelling systems for sustained topical ophthalmic delivery: state of the art and beyond. Destruel PL; Zeng N; Maury M; Mignet N; Boudy V Drug Discov Today; 2017 Apr; 22(4):638-651. PubMed ID: 28017837 [TBL] [Abstract][Full Text] [Related]
12. Gel-Based Materials for Ophthalmic Drug Delivery. Cassano R; Di Gioia ML; Trombino S Gels; 2021 Aug; 7(3):. PubMed ID: 34563016 [TBL] [Abstract][Full Text] [Related]
13. Hydrogel-based ocular drug delivery systems for hydrophobic drugs. Torres-Luna C; Fan X; Domszy R; Hu N; Wang NS; Yang A Eur J Pharm Sci; 2020 Nov; 154():105503. PubMed ID: 32745587 [TBL] [Abstract][Full Text] [Related]
14. Nanotechnology based drug delivery systems for the treatment of anterior segment eye diseases. Onugwu AL; Nwagwu CS; Onugwu OS; Echezona AC; Agbo CP; Ihim SA; Emeh P; Nnamani PO; Attama AA; Khutoryanskiy VV J Control Release; 2023 Feb; 354():465-488. PubMed ID: 36642250 [TBL] [Abstract][Full Text] [Related]
16. Ocular Drug Delivery - New Strategies for Targeting Anterior and Posterior Segments of the Eye. Fangueiro JF; Veiga F; Silva AM; Souto EB Curr Pharm Des; 2016; 22(9):1135-46. PubMed ID: 26675225 [TBL] [Abstract][Full Text] [Related]
17. Lipid Nanoparticles as a Promising Drug Delivery Carrier for Topical Ocular Therapy-An Overview on Recent Advances. Jacob S; Nair AB; Shah J; Gupta S; Boddu SHS; Sreeharsha N; Joseph A; Shinu P; Morsy MA Pharmaceutics; 2022 Feb; 14(3):. PubMed ID: 35335909 [TBL] [Abstract][Full Text] [Related]
18. Recent advances in ocular drug delivery. Achouri D; Alhanout K; Piccerelle P; Andrieu V Drug Dev Ind Pharm; 2013 Nov; 39(11):1599-617. PubMed ID: 23153114 [TBL] [Abstract][Full Text] [Related]
19. The prominence of the dosage form design to treat ocular diseases. Campos PM; Petrilli R; Lopez RFV Int J Pharm; 2020 Aug; 586():119577. PubMed ID: 32622806 [TBL] [Abstract][Full Text] [Related]
20. Advances and limitations of drug delivery systems formulated as eye drops. Jumelle C; Gholizadeh S; Annabi N; Dana R J Control Release; 2020 May; 321():1-22. PubMed ID: 32027938 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]